Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bioequivalence: Overview01:16

Bioequivalence: Overview

892
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
892
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

203
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
203
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Characterization of Lysosomal Hydrolases and Transporters and Their Age-Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs.

Clinical pharmacology and therapeutics·2026
Same author

Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development.

Biologics : targets & therapy·2026
Same author

Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel Oxidation.

Molecular pharmaceutics·2025
Same author

Advancing Monoclonal Antibody Manufacturing: Process Optimization, Cost Reduction Strategies, and Emerging Technologies.

Biologics : targets & therapy·2025
Same author

Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates.

CPT: pharmacometrics & systems pharmacology·2024
Same author

Enzymatic Routes for Chiral Amine Synthesis: Protein Engineering and Process Optimization.

Biologics : targets & therapy·2024
Same journal

Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.

Biologics : targets & therapy·2026
Same journal

Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis.

Biologics : targets & therapy·2026
Same journal

MicroRNA-661 Suppresses Proliferation and Migration of Pulmonary Artery Smooth Muscle Cells and Endothelial Cells by Targeting CCND2.

Biologics : targets & therapy·2026
Same journal

Vunakizumab and Acitretin for Elderly Refractory Generalized Pustular Psoriasis: A Case Report and Comprehensive Literature Review.

Biologics : targets & therapy·2026
Same journal

Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report.

Biologics : targets & therapy·2026
Same journal

Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience.

Biologics : targets & therapy·2026
查看所有相关文章

相关实验视频

Updated: May 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

评估生物类似开发项目:利用净当前价值的分析框架.

Ranjit Ranbhor1, Priyanka Kulkarni2

  • 1Pergament and Cepeda LLC, Florham Park, NJ, 07932, USA.

Biologics : targets & therapy
|April 1, 2025
PubMed
概括
此摘要是机器生成的。

生物类似的发展需要大量的投资. 风险调整后的净当前价值 (NPV) 框架显示,达到2.5亿至3亿美元的峰值销售对于金融可行性至关重要,这是由市场份额和制造效率驱动的.

关键词:
生物类似药的生物类似药.投资评估 投资评估净现在价值分析制药发展 制药发展风险评估 风险评估 风险评估

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

17.7K

相关实验视频

Last Updated: May 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

17.7K

科学领域:

  • 制药经济学 制药经济学
  • 生物技术是生物技术.
  • 医疗保健管理的管理

背景情况:

  • 生物类药物需要强有力的财务评估,因为投资高 (100-250万美元) 和长时间的开发时间表 (6-8年).
  • 传统的仿制药药物评估方法对于生物类似药的开发是不够的.

研究的目的:

  • 为生物类似开发提供一个全面的净当前价值 (NPV) 分析框架.
  • 将技术,监管和商业因素纳入风险调整的NPV方法.

主要方法:

  • 开发一个风险调整的净当前价值 (NPV) 框架.
  • 使用三个单克隆抗体生物相似开发计划的案例研究来验证框架.

主要成果:

  • 成功的生物类似项目需要最低峰值销售额为2.5亿至3亿美元,以获得积极的净净值.
  • 市场份额和制造效率是关键的价值驱动因素.
  • 临床开发占总开发成本的最大部分 (57%).

结论:

  • 早期进入市场,制造业优化和市场份额是生物模拟开发的关键成功因素.
  • 技术复杂性和竞争强度显著影响风险调整后的回报.